Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412109 | 0.82 | DYRK1A (0.39) | DYRK1AKCNH2ACHEEGFRGRIA1 | |
| SCHEMBL4412833 | 0.79 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4415343 | 0.78 | PRKD3 (0.49) | DYRK1AKCNH2ACHEMAPK14MAPK10 | |
| SCHEMBL4408264 | 0.77 | DYRK1A (0.40) | DYRK1AGRIA1MAPK14MAPK10IRAK4 | |
| SCHEMBL4410198 | 0.77 | PTGS2 (0.43) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2926186 | 0.76 | DYRK1A (0.39) | DYRK1AKCNH2ACHEEGFRGRIA1 | |
| SCHEMBL2927863 | 0.74 | DYRK1A (0.41) | DYRK1AKCNH2EGFRMAPK14MAPK10 | |
| SCHEMBL4415845 | 0.72 | MAPK13 (0.52) | DYRK1AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4415840 | 0.72 | MAPK13 (0.52) | DYRK1AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5819409 | 0.69 | KCNH2 (0.62) | KCNH2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2008-12-25 | — | — | US | claimed |
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2008-12-25 | — | — | US | disclosed |
| EP-1833828-A2 | CONDENSED PYRIDINES AS KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006013095-A2 | CONDENSED PYRIDINES AS KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | DYRK1A 1722/4885KCNH2 1643/4885ACHE 3667/4885 |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | DYRK1A 1722/4885KCNH2 1643/4885ACHE 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.